Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.

OBJECTIVES To determine whether the introduction of a community-acquired pneumonia (CAP) severity assessment tool to guide antibiotic selection could reduce broad-spectrum antibiotic prescribing without compromising patient safety. METHODS A prospective before and after evaluation study. Empirical antibiotic prescribing was studied for 18 months from June 2006 to January 2008 (pre-intervention) and then for 18 months following the implementation of a CURB65-guided antibiotic therapy guideline in June 2008. The primary outcome was the use of broad-spectrum antibiotics (cephalosporin, amoxicillin plus clavulanic acid and macrolides) in patients with CAP. Safety outcomes were 30 day mortality, requirement for mechanical ventilation and/or vasopressor support (MV/VS), development of complicated pneumonia, time to clinical stability (TCS) and length of hospital stay. RESULTS The introduction of CURB65-guided therapy resulted in an overall reduction in the prescription of cephalosporins (from 27.1% of patients receiving this agent in the overall pre-intervention cohort to 8.0% in the post-intervention cohort, P < 0.0001) and macrolides (72.8% to 58.7%, P < 0.0001), particularly among low-risk patients. There was a corresponding increase in the prescription of the narrower-spectrum agent amoxicillin (29.7% to 41.7%, P < 0.0001) and an increase in the use of amoxicillin monotherapy (10.4% to 29.9%, P < 0.0001). Co-amoxiclav use increased slightly as this agent replaced cephalosporins as first-line treatment for severe CAP. The guideline had no impact on 30 day mortality, MV/VS, complicated pneumonia, TCS or length of stay. Following the intervention, adherence to national guidelines increased from 25.4% of prescriptions to 61.9%, suggesting the potential for further improvements. CONCLUSIONS CURB65-guided antibiotic therapy was associated with a significant decrease in broad-spectrum antibiotic use. The intervention was safe with no impact on mortality, treatment failure or clinical response.

[1]  A. Akram,et al.  Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis , 2010, Thorax.

[2]  J. Chalmers,et al.  Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. , 2010, The Journal of antimicrobial chemotherapy.

[3]  W. Lim,et al.  BTS guidelines for the management of community acquired pneumonia in adults: update 2009 , 2009, Thorax.

[4]  A. Hill,et al.  Severity assessment in community-acquired pneumonia: a review. , 2009, QJM : monthly journal of the Association of Physicians.

[5]  T. Welte,et al.  Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. , 2009, The Journal of antimicrobial chemotherapy.

[6]  W. Lim,et al.  Does early review by a respiratory physician lead to a shorter length of stay for patients with non-severe community-acquired pneumonia? , 2009, Thorax.

[7]  W. Lim,et al.  Local guidelines for management of adult community acquired pneumonia: a survey of UK hospitals , 2009, Thorax.

[8]  A. Tessmer,et al.  Impact of intravenous b -lactam/macrolide versus b -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia , 2009 .

[9]  J. Cooke,et al.  Clostridium difficile infection: how to deal with the problem , 2009 .

[10]  M. Fine,et al.  The pneumonia severity index: a decade after the initial derivation and validation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Corrao,et al.  Can CAP guideline adherence improve patient outcome in internal medicine departments? , 2008, European Respiratory Journal.

[12]  A. Hill,et al.  Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia , 2008, Thorax.

[13]  A. Hill,et al.  C-reactive protein is an independent predictor of severity in community-acquired pneumonia. , 2008, The American journal of medicine.

[14]  G. Barlow,et al.  Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. , 2008, The Journal of antimicrobial chemotherapy.

[15]  J. Sung,et al.  Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong , 2007, Thorax.

[16]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  G. Barlow,et al.  The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  J. Black,et al.  A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia , 2006, Thorax.

[19]  A. Bilbao,et al.  Validation of a predictive rule for the management of community-acquired pneumonia , 2006, European Respiratory Journal.

[20]  M. Fine,et al.  Effect of Increasing the Intensity of Implementing Pneumonia Guidelines , 2005, Annals of Internal Medicine.

[21]  M. Bonten,et al.  Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  A. Torres,et al.  Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. , 2005, American journal of respiratory and critical care medicine.

[23]  Donald M Yealy,et al.  Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. , 2005, The American journal of medicine.

[24]  I. Gould,et al.  Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000 , 2004, Emerging infectious diseases.

[25]  F. Tubau,et al.  Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. , 2004, Archives of internal medicine.

[26]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[27]  M. Fine,et al.  Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. , 2002, Archives of internal medicine.

[28]  M. Fine,et al.  Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. , 2002, Archives of internal medicine.

[29]  M. Leinonen,et al.  role of serum troponin levels combined with electrocardiographic findings Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines , 2001 .

[30]  S. Unal,et al.  Antimicrobial-drug use and methicillin-resistant Staphylococcus aureus. , 2001, Emerging infectious diseases.

[31]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Wilcox.  Respiratory antibiotic use and Clostridium difficile infection: is it the drugs or is it the doctors? , 2000, Thorax.

[33]  M. Fine,et al.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. , 1999, Archives of internal medicine.

[34]  D. Singer,et al.  Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. , 1998, Archives of internal medicine.

[35]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[36]  J. Starr,et al.  Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime , 1995, BMJ.

[37]  Robert Fritz,et al.  The Path of Least Resistance , 1986 .